Organon & Co. (OGN)

$11.01 +0.07 (0.64%)
Market Cap 2.84B
Revenue (ttm) 6.40B
Net Income (ttm) 864.00M
EPS (ttm) N/A
PE Ratio 3.11
Forward PE 3.02
Profit Margin 13.49%
Debt to Equity Ratio 12.14
Volume 4,256,400
Avg Vol 4,109,884
Day's Range N/A - N/A
Shares Out 259.97M
Stochastic %K 81%
Beta 0.63
Analysts Sell
Price Target $13.17

Company Profile

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 551 430 6900
Address:
30 Hudson Street, Floor 33, Jersey City, United States
secondtimearound
secondtimearound Oct. 1 at 3:38 PM
$OGN got a gap to fill above
0 · Reply
frankster
frankster Sep. 30 at 9:52 PM
$BMY $MRK $OGN $PFE here’s our first biggest catalyst! These drug companies negotiating the a deal with the administration on price discounts and direct to consumer is a major step and on top of it getting a long break from paying tariffs. They’re all easily undervalued 30-40% imo.
0 · Reply
highnihilism
highnihilism Sep. 30 at 12:11 PM
$EC Ecopetrol: 52 trades, $18K vs $26K avg (0.69x). $15K calls / $3K puts. $OGN Organon: 112 trades, $40K vs $139K avg (0.29x). $15K calls / $25K puts. $WVE Wave Life Sciences: 91 trades, $77K vs $91K avg (0.85x). $15K calls / $62K puts. $OS Onestream: 77 trades, $210K vs $125K avg (1.67x). $15K calls / $195K puts.
0 · Reply
frankster
frankster Sep. 30 at 11:54 AM
$BMY lost 25% value this year! as if AI not going to revolutionize cancer research and provide efficiency for these major biotech players! it’s comical how money has left this sector. I think it’ll come back with vengeance in a short period once few catalysts hit the wire. $PFE $MRK $OGN
0 · Reply
SweepCastApp
SweepCastApp Sep. 26 at 12:37 PM
$OGN: TRADE CALL contracts spotted 60 @ 4.57, Strike 7.5, Exp 1/21/2028, Premium $27,420, Sentiment NEUTRAL
0 · Reply
mdes
mdes Sep. 24 at 4:04 PM
$LYB $OGN $WEN $UPS $DOW still no mercy here .. sucks holding these that don't give even trading bounces anymore
0 · Reply
mdes
mdes Sep. 21 at 9:15 PM
$LYB $OGN $WEN $UPS worst hit stocks over last 12 months, even rate cuts not helping (may be pfe but it showed some life in between)
1 · Reply
MrNotSoNice
MrNotSoNice Sep. 15 at 10:44 PM
$OGN Can this company grow revenue and pay down debt? 🤔
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Sep. 14 at 1:10 PM
The attachment compiles certain valuation related data points on 9 mature commercial-stage bios (3 in oncology & 6 in non-oncology). For the more mature bios in this peer group, we consider enterprise value related multiples the best predictor of value potential (since all 9 are long past traditional M&A exit timelines). $OGN appears to be the most leveraged. Should they be able to service the debt (not considered in EPS) then... We understand $PTCT first meaningful FDA approval came in 2017 so they are the youngest in this peer group. They are the only bio of the 9 still not profitable. $BMRN is hovering near 52-week lows yet still appears to trade at revenue multiples consistent with others in this peer group. $ACAD & $ALKS have almost identical multiples. ACAD just got a major IP extension. This is not investment advice as we do not follow the non-oncology bios in this peer group in any detail. We'd otherwise appreciate genuine feedback. Are we missing a data point to consider?
1 · Reply
Obliviously
Obliviously Sep. 12 at 5:06 AM
$OGN Momentum looks favorable. If higher volume confirms, this could be a real bounce, not just a short-term tick.
0 · Reply
Latest News on OGN
European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Sep 19, 2025, 6:00 AM EDT - 15 days ago

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Sep 2, 2025, 5:30 AM EDT - 4 weeks ago

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Organon: Valuation Discount Offset By Structural Headwinds

Aug 12, 2025, 2:22 PM EDT - 7 weeks ago

Organon: Valuation Discount Offset By Structural Headwinds

Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)

Aug 6, 2025, 11:59 AM EDT - 2 months ago

Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)

Organon & Co. (OGN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 1:10 PM EDT - 2 months ago

Organon & Co. (OGN) Q2 2025 Earnings Call Transcript

Organon Reports Results for the Second Quarter Ended June 30, 2025

Aug 5, 2025, 7:30 AM EDT - 2 months ago

Organon Reports Results for the Second Quarter Ended June 30, 2025

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025

Jul 22, 2025, 7:30 AM EDT - 2 months ago

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

Jul 21, 2025, 4:02 PM EDT - 2 months ago

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 20, 2025, 10:55 AM EDT - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 11, 2025, 9:37 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

OGN COURT NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law by the July 22 Legal Deadline (NYSE:OGN)

Jul 10, 2025, 8:18 AM EDT - 3 months ago

OGN COURT NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law by the July 22 Legal Deadline (NYSE:OGN)

Trade Tracker: Jenny Harrington sells Organon and buys Vici Properties

Jul 8, 2025, 1:14 PM EDT - 3 months ago

Trade Tracker: Jenny Harrington sells Organon and buys Vici Properties

VICI

Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis

Jul 7, 2025, 7:30 AM EDT - 3 months ago

Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 3, 2025, 8:25 AM EDT - 3 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Karolinska Development receives update from Organon concerning OG-6219

Jul 3, 2025, 1:00 AM EDT - 3 months ago

Karolinska Development receives update from Organon concerning OG-6219

Organon to halt development of endometriosis pain drug after mid-stage trial failure

Jul 2, 2025, 8:01 AM EDT - 3 months ago

Organon to halt development of endometriosis pain drug after mid-stage trial failure

Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain

Jul 2, 2025, 7:30 AM EDT - 3 months ago

Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain

OGN INVESTOR DEADLINE: Organon & Co. Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

Jun 28, 2025, 7:46 AM EDT - 3 months ago

OGN INVESTOR DEADLINE: Organon & Co. Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon Lawsuit - OGN

Jun 26, 2025, 9:00 AM EDT - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon Lawsuit - OGN

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon & Co. Lawsuit - OGN

Jun 23, 2025, 9:00 AM EDT - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon & Co. Lawsuit - OGN

OGN COURT REMINDER: Organon & Co. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

Jun 20, 2025, 9:06 AM EDT - 3 months ago

OGN COURT REMINDER: Organon & Co. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

OGN NOTICE: Did Organon & Co. Mislead Investors? Contact BFA Law by July 22 Court Deadline if You Suffered Losses (NYSE:OGN)

Jun 18, 2025, 8:38 AM EDT - 3 months ago

OGN NOTICE: Did Organon & Co. Mislead Investors? Contact BFA Law by July 22 Court Deadline if You Suffered Losses (NYSE:OGN)

Organon: A Look Beyond The Dividend Cut

Jun 18, 2025, 1:02 AM EDT - 3 months ago

Organon: A Look Beyond The Dividend Cut

OGN SHAREHOLDER REPORT: Organon & Co. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

Jun 16, 2025, 8:18 AM EDT - 3 months ago

OGN SHAREHOLDER REPORT: Organon & Co. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

OGN LEGAL NOTICE: Lose Money when Organon & Co. Stock Plummeted 27%? Contact BFA Law by the July 22 Court Deadline (NYSE:OGN)

Jun 10, 2025, 8:47 AM EDT - 4 months ago

OGN LEGAL NOTICE: Lose Money when Organon & Co. Stock Plummeted 27%? Contact BFA Law by the July 22 Court Deadline (NYSE:OGN)

OGN INVESTOR NEWS: Organon & Co. has been Sued for Securities Fraud – Contact BFA Law before July 22 Deadline (NYSE:OGN)

Jun 8, 2025, 8:18 AM EDT - 4 months ago

OGN INVESTOR NEWS: Organon & Co. has been Sued for Securities Fraud – Contact BFA Law before July 22 Deadline (NYSE:OGN)

Shareholders who lost money on Organon & Co. (NYSE: OGN). Should Contact Wolf Haldenstein

Jun 6, 2025, 11:51 AM EDT - 4 months ago

Shareholders who lost money on Organon & Co. (NYSE: OGN). Should Contact Wolf Haldenstein

OGN LAWSUIT: Organon & Co. Lawsuit Alleges Securities Fraud Violations - Investors Notified to Contact BFA Law

Jun 4, 2025, 3:46 PM EDT - 4 months ago

OGN LAWSUIT: Organon & Co. Lawsuit Alleges Securities Fraud Violations - Investors Notified to Contact BFA Law

secondtimearound
secondtimearound Oct. 1 at 3:38 PM
$OGN got a gap to fill above
0 · Reply
frankster
frankster Sep. 30 at 9:52 PM
$BMY $MRK $OGN $PFE here’s our first biggest catalyst! These drug companies negotiating the a deal with the administration on price discounts and direct to consumer is a major step and on top of it getting a long break from paying tariffs. They’re all easily undervalued 30-40% imo.
0 · Reply
highnihilism
highnihilism Sep. 30 at 12:11 PM
$EC Ecopetrol: 52 trades, $18K vs $26K avg (0.69x). $15K calls / $3K puts. $OGN Organon: 112 trades, $40K vs $139K avg (0.29x). $15K calls / $25K puts. $WVE Wave Life Sciences: 91 trades, $77K vs $91K avg (0.85x). $15K calls / $62K puts. $OS Onestream: 77 trades, $210K vs $125K avg (1.67x). $15K calls / $195K puts.
0 · Reply
frankster
frankster Sep. 30 at 11:54 AM
$BMY lost 25% value this year! as if AI not going to revolutionize cancer research and provide efficiency for these major biotech players! it’s comical how money has left this sector. I think it’ll come back with vengeance in a short period once few catalysts hit the wire. $PFE $MRK $OGN
0 · Reply
SweepCastApp
SweepCastApp Sep. 26 at 12:37 PM
$OGN: TRADE CALL contracts spotted 60 @ 4.57, Strike 7.5, Exp 1/21/2028, Premium $27,420, Sentiment NEUTRAL
0 · Reply
mdes
mdes Sep. 24 at 4:04 PM
$LYB $OGN $WEN $UPS $DOW still no mercy here .. sucks holding these that don't give even trading bounces anymore
0 · Reply
mdes
mdes Sep. 21 at 9:15 PM
$LYB $OGN $WEN $UPS worst hit stocks over last 12 months, even rate cuts not helping (may be pfe but it showed some life in between)
1 · Reply
MrNotSoNice
MrNotSoNice Sep. 15 at 10:44 PM
$OGN Can this company grow revenue and pay down debt? 🤔
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Sep. 14 at 1:10 PM
The attachment compiles certain valuation related data points on 9 mature commercial-stage bios (3 in oncology & 6 in non-oncology). For the more mature bios in this peer group, we consider enterprise value related multiples the best predictor of value potential (since all 9 are long past traditional M&A exit timelines). $OGN appears to be the most leveraged. Should they be able to service the debt (not considered in EPS) then... We understand $PTCT first meaningful FDA approval came in 2017 so they are the youngest in this peer group. They are the only bio of the 9 still not profitable. $BMRN is hovering near 52-week lows yet still appears to trade at revenue multiples consistent with others in this peer group. $ACAD & $ALKS have almost identical multiples. ACAD just got a major IP extension. This is not investment advice as we do not follow the non-oncology bios in this peer group in any detail. We'd otherwise appreciate genuine feedback. Are we missing a data point to consider?
1 · Reply
Obliviously
Obliviously Sep. 12 at 5:06 AM
$OGN Momentum looks favorable. If higher volume confirms, this could be a real bounce, not just a short-term tick.
0 · Reply
Winning_calls
Winning_calls Sep. 8 at 3:36 PM
$OGN 😉😉
0 · Reply
Winning_calls
Winning_calls Sep. 8 at 3:19 AM
$OGN pick me up @ $10.34
0 · Reply
frankster
frankster Sep. 7 at 1:57 AM
$OGN it's dirt cheap but clearly market doesn't care for now. perhaps rate cuts and some good news will finally lit some fire under this. 20-30 stock in few yrs imo. got 10,000 shares and not looking at it for awhile.
0 · Reply
JClem_Stocks
JClem_Stocks Sep. 5 at 4:20 PM
$OGN I’ll keep adding if it goes under $10 again…. Easy $15-$20 per share. Already undervalued, but with latest advancements, should see market catch up to it…
0 · Reply
biotechworld
biotechworld Sep. 3 at 8:07 PM
$OGN started position. Looks good 👍
0 · Reply
Chickenstick1
Chickenstick1 Sep. 3 at 7:26 PM
$OGN $13
0 · Reply
handmedown1
handmedown1 Sep. 3 at 7:01 PM
$OGN $BMY someone will buy this. Pe of 1
1 · Reply
CDMO
CDMO Aug. 26 at 4:51 PM
$OGN trash
0 · Reply
handmedown1
handmedown1 Aug. 26 at 3:23 PM
$OGN surprised no one buys this
0 · Reply
Chickenstick1
Chickenstick1 Aug. 22 at 8:00 PM
$OGN $15 on cost of debt.
0 · Reply
tradeitbetit
tradeitbetit Aug. 6 at 6:32 PM
$OGN PSA this company has a PE of $2 lol
1 · Reply
seazest
seazest Aug. 6 at 4:06 PM
$OGN Another few weeks it should break 10 dollars but right it is a pos.
1 · Reply